|Bid||140.00 x 800|
|Ask||141.47 x 900|
|Day's Range||141.19 - 144.67|
|52 Week Range||103.31 - 306.72|
|Beta (5Y Monthly)||0.00|
|PE Ratio (TTM)||6.51|
|Earnings Date||Aug. 05, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||146.50|
Quidel (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quidel (NASDAQ: QDEL) is a testing company that's been experiencing tremendous sales growth over the past year, largely because of the popularity of its COVID-19 tests amid the pandemic. Shares are down 17% year to date (while the S&P 500 is up 18%), and it's possible that Quidel's stock could fall even lower before the year is over. One of the reasons I was bullish on the healthcare stock was the potential for Quidel to play a major role in testing for companies and schools as they open back up.
SAN DIEGO, July 26, 2021--Quidel Corporation (NASDAQ: QDEL) ("Quidel"), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its entry into agreements with Beckman Coulter resolving the ongoing litigation with Beckman Coulter and providing for the transition of the BNP Business to Beckman Coulter. Under these agreements, Beckman Coulter will pay Quidel cash payments of between $70 million and $75 million per year throu